Drug Target for Cancer: NTRK2

Drug Targets for Cancer: NTRK2 and Cancer

NTRK2 (also known as TrkB) - is an oncogene implicated in the tumorigenesis of neuroblastoma, amongst others. The related NTRK1 and NTRK3 genes have previously been shown to be activated by fusion events (e.g. TPM3:NTRK1 in papillary thyroid cancer and ETV6:NTRK3 in multiple cancers). The QKI:NTRK2 and NACC2:NTRK2 fusions identified here were verified by PCR. Both 5′ partners contain dimerization domains, and are therefore predicted to induce ligand-independent dimerization. Interestingly, N-terminal TrkB truncation has recently been shown to induce transformation of neural crest cells. The downstream effects of TrkB activation are mediated at least in part via MAPK pathway activation.

Drug Targets for Cancer: NTRK2 related Products

Other vital drug targets for cancer like NTRK2:

Drug Targets for Cancer: NTRK2 Related Reference

Jones DTW, Hutter B, J?ger N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature genetics. 2013;45(8):927-932.

Drug Targets for Cancer: NTRK2 Related Information